AGIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Agios Pharmaceuticals Inc (AGIO) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. The company's strong financial growth, positive regulatory outlook for its drug pipeline, and hedge fund interest make it a compelling opportunity. Despite the lack of recent news or congress trading data, the technical indicators and analyst sentiment support a positive long-term view.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 73.742, and moving averages are converging, suggesting potential price consolidation. The stock is trading near its pivot level of 34.171, with resistance at 35.516 and support at 32.827.
Hedge funds are significantly increasing their positions, with a 297.63% increase in buying over the last quarter.
Analysts have raised price targets, with Citi placing an 'upside 90-day catalyst watch' due to a favorable regulatory outlook for mitapivat in sickle cell disease.
Financials show strong revenue growth of 86.09% YoY and improved gross margin of 90.59%.
The company remains unprofitable, with a net income of -$108.03M in Q4
Lack of recent news or congress trading data to provide additional sentiment insights.
In Q4 2025, Agios Pharmaceuticals reported an 86.09% YoY increase in revenue to $19.97M. Net income improved by 11.93% YoY but remains negative at -$108.03M. EPS increased by 9.47% YoY to -1.85, and gross margin improved to 90.59%, up 2.64% YoY.
Analysts have raised price targets recently, with JPMorgan increasing its target to $36, Goldman Sachs to $32, and Citi to $46. Citi maintains a Buy rating and highlights a favorable regulatory outlook for mitapivat, with potential catalysts in the next 90 days.
